LOGIN  |  REGISTER
C4 Therapeutics
Cue Biopharma

ICU Medical Announces Time of Fourth Quarter 2022 Earnings Conference Call

February 13, 2023 | Last Trade: US$140.54 2.11 -1.48

SAN CLEMENTE, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) --  ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter 2022 earnings release and conference call.

The Company will release its fourth quarter 2022 results on Monday, February 27th, 2023 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Monday, February 27th, 2023. The call can be accessed at (877) 300-8521, conference ID 10174731. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's website at www.icumed.com, clicking on the Investors tab, clicking on the Webcast icon and following the prompts. The webcast will also be available by replay.

About ICU Medical

ICU Medical (Nasdaq:ICUI) is a global leader in infusion systems, infusion consumables, and high-value critical care products used in hospital, alternate site, and home care settings. Our team is focused on providing quality, innovation, and value to our clinical customers worldwide. ICU Medical is headquartered in San Clemente, California. For more information about ICU Medical, go to www.icumed.com and follow us on LinkedIn, Twitter, and Facebook.

CONTACT:
ICU Medical, Inc.
Brian Bonnell, Chief Financial Officer
(949) 366-2183

ICR, Inc.
John Mills, Managing Partner
(646) 277-1254

Terns Pharmaceuticals

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page